Business Context and Reporting Period
Pediatrix Medical Group, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2001. The Company is a provider of pediatric medical services. The reporting period is significantly impacted by the completion of a merger with Magella Healthcare Corporation on May 15, 2001, and the acquisition of three additional physician group practices during the six months ended June 30, 2001.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Net Patient Service Revenue | $147,056,000 | $114,587,000 |
| Income from Operations | $19,473,000 | $7,877,000 |
| Net Income | $9,961,000 | $3,087,000 |
| Diluted EPS | $0.53 | $0.20 |
| Cash and Cash Equivalents (End of Period) | $4,440,000 | $1,197,000 |
| Net Cash Provided by Operating Activities | $28,650,000 | $10,473,000 |
| Line of Credit Outstanding | $41,500,000 | $23,500,000 (Dec 31, 2000) |
| Long-Term Debt | $12,792,000 | $0 |
| Total Assets | $546,916,000 | $324,734,000 (Dec 31, 2000) |
Liquidity: The Company reported a working capital deficit of approximately $12.6 million as of June 30, 2001, primarily due to the classification of the $41.5 million line of credit as a current liability. Excluding the line of credit, working capital increased by $3.3 million compared to the prior year-end.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 28.3% year-over-year for the six-month period. Management attributes approximately 77.3% of the organic increase to new units acquired, with same-unit revenue growing 5.0% due to higher patient acuity and volume.
- Acquisition Impact: The merger with Magella and other acquisitions drove significant increases in operating expenses. Salaries and benefits rose 17.9%, and depreciation and amortization increased 28.2% due to goodwill amortization.
- Profitability: Net income increased 222% compared to the prior year. This comparison is influenced by a $6.5 million charge recorded in the second quarter of 2000 related to an increase in the allowance for contractual adjustments and uncollectible accounts. Excluding this charge, net income increased approximately 45.9%.
- Debt Structure: The Company assumed approximately $12.8 million in convertible subordinated notes in connection with the Magella merger. Borrowings on the line of credit increased to fund debt repayment and acquisitions.
Guidance, Outlook, Risks, and Contingencies
Outlook and Financing: The Company's $75 million line of credit matures on September 30, 2001. Management is negotiating to obtain financing beyond this date but stated there is no assurance that financing will be obtained on similar terms. The Company believes current funds and operating cash flow will meet requirements for the next 12 months pending new financing.
Legal Proceedings and Contingencies:
- Securities Class Action: A federal securities class action regarding billing practices and financial statements (filed Feb 1999) is in the discovery stage. A pre-trial conference is set for September 14, 2001. The Company believes claims are without merit but acknowledges potential damages could exceed insurance coverage.
- Government Investigations: Investigations into Medicaid billing practices in Arizona and Florida were settled in 2000 with payments of $220,000 and $40,000, respectively. An investigation in Colorado remains ongoing, and inquiries from other states are possible.
- Accounting Changes: The Company is assessing the impact of new FASB standards (FAS 141 and FAS 142) regarding business combinations and goodwill, effective for transactions after June 30, 2001.
Investor Verification Checklist
- Verify the status of negotiations for the extension or refinancing of the $75 million line of credit maturing September 30, 2001.
- Monitor the progress of the federal securities class action lawsuit and the ongoing Colorado Medicaid investigation for potential material adverse effects.
- Review the integration progress of the Magella Healthcare Corporation merger and the impact on same-unit revenue growth in subsequent quarters.
- Assess the sustainability of operating margins given the increased amortization expenses from recent acquisitions.
- Confirm compliance with financial covenants associated with the line of credit and convertible notes.